Edwards Lifesciences Corporation
EW
Rank in Stocks
#483
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Share Price
$87.29
Market Cap
$50.31B
Change (1 day)
0.96%
Change (1 year)
16.95%
Country
US
Trade Edwards Lifesciences Corporation (EW)
Category
Healthcare
P/E ratio for Edwards Lifesciences Corporation (EW)
P/E ratio as of October 2026 TTM: 49.68
According to Edwards Lifesciences Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 49.68. At the end of 2024 the company had a P/E ratio of 10.60.
P/E ratio history for Edwards Lifesciences Corporation from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 49.68 | 6.99% |
| 2025 | 46.44 | 338.15% |
| 2024 | 10.60 | -67.87% |
| 2023 | 32.99 | 8.70% |
| 2022 | 30.35 | -43.51% |
| 2021 | 53.72 | -22.12% |
| 2020 | 68.98 | 48.61% |
| 2019 | 46.42 | 4.62% |
| 2018 | 44.37 | 16.12% |
| 2017 | 38.21 | 9.03% |
| 2016 | 35.04 | 1.90% |
| 2015 | 34.39 | 105.62% |
| 2014 | 16.73 | -10.81% |
| 2013 | 18.75 | -46.93% |
| 2012 | 35.34 | 3.23% |
| 2011 | 34.23 | -18.82% |
| 2010 | 42.16 | 97.55% |
| 2009 | 21.34 | -10.28% |
| 2008 | 23.79 | 2.00% |
| 2007 | 23.32 | 10.59% |
| 2006 | 21.09 | -32.57% |
| 2005 | 31.27 | -97.84% |
| 2004 | 1.45K | 6,328.22% |
| 2003 | 22.50 | -16.59% |
| 2002 | 26.98 | -119.89% |
| 2001 | -135.62 | 3,477.63% |
| 2000 | -3.79 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 33.11 | -33.36% |
US
|
|
| 21.39 | -56.95% |
IE
|
|
| 28.94 | -41.74% |
US
|
|
| 17.34 | -65.10% |
US
|
|
| - | - |
DE
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.